Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 4/20 | 0.37 |
| ▸ | ACHE | P22303 | 6/20 | 0.35 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.35 |
| ▸ | CDK2 | P24941 | 3/20 | 0.35 |
| ▸ | TTK | P33981 | 2/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | CDK7 | P50613 | 1/20 | 0.34 |
| ▸ | CCNH | P51946 | 1/20 | 0.34 |
| ▸ | MNAT1 | P51948 | 1/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2929192 | 0.96 | SYK (0.40) | SYKACHECCNA2CDK2TTK | |
| Trifluoroacetic Acid SCHEMBL4890779 | 0.85 | CDK2 (0.43) | SYKCCNA2CDK2TTKAURKB | |
| Trifluoroacetic Acid SCHEMBL2928635 | 0.80 | DYRK1A (0.47) | TTKHRH4 | |
| SCHEMBL2927770 | 0.80 | CDK2 (0.47) | SYKCCNA2CDK2TTKAURKB | |
| SCHEMBL2928003 | 0.79 | HRH4 (0.42) | SYKCCNA2CDK2TTKAURKB | |
| Trifluoroacetic Acid SCHEMBL2930403 | 0.78 | CDK2 (0.41) | CCNA2CDK2TTKAURKBHRH4 | |
| SCHEMBL2933784 | 0.77 | PIM3 (0.42) | SYKHPGD | |
| SCHEMBL2930971 | 0.76 | DYRK1A (0.47) | CCNA2CDK2TTKHRH4 | |
| SCHEMBL2929057 | 0.75 | SYK (0.43) | SYKCCNA2CDK2TTKAURKB | |
| SCHEMBL2929271 | 0.74 | KDR (0.43) | HRH4MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | SYK 1798/4885ACHE 2008/4885CCNA2 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.